Synonyms: ANEB-001 | ANEB001
Compound class:
Synthetic organic
Comment: The chemical structure for selonabant was obtained from WHO proposed INN list 131 (August 2024). The INN record describes the compound as a cannabinoid receptor 1 (CB1) antagonist. A chemical structure match via PubChem indicates that this is the INN for Anebulo Pharmaceutical's clinical lead ANEB-001, which is a high affinity, competitive CB1 antagonist. It is proposed as a rapidly acting antidote for acute cannabinoid intoxication. The structure for selonabant was originally claimed in a Vernalis patent [1] (named V24343 by Vernalis), but it is claimed specifically as ANEB-001 in WO2022109043A1 [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Download 2D Structure ![]() |
|
Canonical SMILES | Download |
Isomeric SMILES | Download |
InChI standard identifier | Download |
InChI standard key | Download |
Molecular structure representations generated using Open Babel